| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/25/2009 | CA2326815C Process for preparation of pyridine derivatives |
| 08/20/2009 | WO2009102805A1 Indole compounds and methods of use thereof |
| 08/20/2009 | WO2009102570A2 Treatments for neuropathy |
| 08/20/2009 | WO2009102443A2 Octanoic acid formulations and methods of treatment using the same |
| 08/20/2009 | WO2009101942A1 Screening method |
| 08/20/2009 | WO2009101917A1 Bicycloamine derivative |
| 08/20/2009 | WO2009101812A1 Glutamic acid transporter inhibitor |
| 08/20/2009 | WO2009101700A1 Bioassay method for yokkansan |
| 08/20/2009 | WO2009101616A1 Novel conjugates for treating neurodegenerative diseases and disorders |
| 08/20/2009 | WO2009101458A2 New polymorph and amorphous forms of desvenlafaxine fumarate |
| 08/20/2009 | WO2009101185A2 A polymorphic form of a pyrazino [2, 3-h] [3] benzazepine derivative |
| 08/20/2009 | WO2009101018A2 3-alkyl-piperazine derivatives and uses thereof |
| 08/20/2009 | WO2009100994A1 Piperidine sulfonamide derivatives |
| 08/20/2009 | WO2009082268A3 LIGANDS OF α-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF |
| 08/20/2009 | WO2009065596A3 Use of mnk inhibitors for the treatment of alzheimer's disease |
| 08/20/2009 | WO2009047296A3 Metabotropic glutamate receptor modulators for the treatment op parkinson's disease |
| 08/20/2009 | WO2009046872A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033808A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033789A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033765A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009033754A3 Use of a peptide as a therapeutic agent |
| 08/20/2009 | WO2009025791A3 Purification of armodafinil |
| 08/20/2009 | US20090209655 Isoflavone metabolites |
| 08/20/2009 | US20090209638 Treatment for depressive disorders |
| 08/20/2009 | US20090209634 Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| 08/20/2009 | US20090209633 Treatment of Pain With Resiniferatoxin and Related Analogs |
| 08/20/2009 | US20090209622 Diagnosis of anxiety disorders |
| 08/20/2009 | US20090209617 Duloxetine salts |
| 08/20/2009 | US20090209615 Inhibitors of matrix metalloproteinases to treat neurological disorders |
| 08/20/2009 | US20090209608 Deuterium-enriched asenapine |
| 08/20/2009 | US20090209597 Imidazole derivatives and their use for modulating the gaba alpha receptor complex |
| 08/20/2009 | US20090209595 Method of treating of demyelinating diseases or conditions |
| 08/20/2009 | US20090209594 Method of treating of demyelinating diseases or conditions |
| 08/20/2009 | US20090209585 Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| 08/20/2009 | US20090209579 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| 08/20/2009 | US20090209575 Method for treating neuropathic pain and associated syndromes |
| 08/20/2009 | US20090209570 6-Aminomorphinane Derivatives, Method for the Production and Use Thereof |
| 08/20/2009 | US20090209569 Selective opioid compounds |
| 08/20/2009 | US20090209568 Spiro [Benzopyran] or Spiro [Benzofuran] Derivatives Which Inhibit the Sigma Receptor |
| 08/20/2009 | US20090209563 Pyridinoylpiperidines as 5-HT1F agonists |
| 08/20/2009 | US20090209562 Fused ring 4-oxopyrimidine derivative |
| 08/20/2009 | US20090209559 Pharmaceutical compounds |
| 08/20/2009 | US20090209553 Arylpiperazine derivatives and uses thereof |
| 08/20/2009 | US20090209550 Substituted triazolopyridines |
| 08/20/2009 | US20090209545 Besylate Salts of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-oxo-6,7-dihydro-5H-Pyrrolo[3,4-b]Pyrazine |
| 08/20/2009 | US20090209540 Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same |
| 08/20/2009 | US20090209536 Aminoquinazoline cannabinoid receptor modulators for treatment of disease |
| 08/20/2009 | US20090209533 Aldh-2 inhibitors in the treatment of addiction |
| 08/20/2009 | US20090209517 Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders |
| 08/20/2009 | US20090209486 Nutraceuticals for defense against viral diseases, infections such as traveler's diarrhea, and gastrointestinal disorders; mannose, n-acetylneuraminic acid, fucose, n-acetylgalactosamine, xylose with one of glucosamine HCL, glucosamine sulfate, galactose, or flavorings, and also e.g. honey or olive oil |
| 08/20/2009 | US20090209480 Central administration of stable formulations of therapeutic agents for cns conditions |
| 08/20/2009 | US20090209465 MCT1 Transporters Expressed in Blood Brain Barrier Cells |
| 08/20/2009 | US20090209037 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 08/20/2009 | US20090209004 Human il-1 beta antagonists |
| 08/20/2009 | US20090208595 Extract of plant Dendrobii caulis and preparing process thereof |
| 08/20/2009 | US20090208587 Dairy based foodstuff containing central nervous system lipids |
| 08/20/2009 | US20090208579 Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| 08/20/2009 | US20090208504 Polypeptides involved in immune response |
| 08/20/2009 | US20090208499 adminstering N-(phosphonomethyl)-proline free of N-(phosphonomethyl)-glycine or N,N-bis(phosphonomethyl)-glycine to a patient to treat cosmetic conditions and medical disorders, symptoms or syndromes associated with at least one of a nervous, vascular, musculoskeletal or cutaneous system |
| 08/20/2009 | US20090208425 Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone |
| 08/20/2009 | US20090208415 Tropane compounds |
| 08/20/2009 | US20090208414 Method for the use of [11c] carbon monoxide in labeling synthesis of 11c-labelled ketones by photo-induced free radical carbonylation |
| 08/20/2009 | CA2715282A1 Indole compounds and methods of use thereof |
| 08/20/2009 | CA2714676A1 Treatments for neuropathy |
| 08/20/2009 | CA2714591A1 Bicycloamine derivative |
| 08/20/2009 | CA2714331A1 Selective opioid compounds |
| 08/20/2009 | CA2713713A1 Piperidine sulfonamide derivatives |
| 08/20/2009 | CA2713378A1 3-alkyl-piperazine derivatives and uses thereof |
| 08/20/2009 | CA2712946A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 08/19/2009 | EP2090657A2 Anti-IL-12 antibodies, compositions, methods and uses |
| 08/19/2009 | EP2090583A1 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 08/19/2009 | EP2090578A1 Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta |
| 08/19/2009 | EP2090576A1 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| 08/19/2009 | EP2090571A1 Pyrimidine derivates, medicaments comprising them, their use and process of their preparation |
| 08/19/2009 | EP2090312A1 (S,S) reboxetine for treating attention deficit disorder |
| 08/19/2009 | EP2090311A1 Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| 08/19/2009 | EP2090310A1 Method for prevention of coloration in donepezil-containing skin adhesive preparation, and method for reducing the production of donepezil analogue in donepezil-containing skin adhesive preparation |
| 08/19/2009 | EP2090309A1 Use of thiazole inhibitors of fatty acid oxidation of formula (I) for the treatment of Alzheimer's disease and other neurological conditions |
| 08/19/2009 | EP2089417A2 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| 08/19/2009 | EP2089416A1 Depsipeptides and their therapeutic use |
| 08/19/2009 | EP2089415A1 Depsipeptides and their therapeutic use |
| 08/19/2009 | EP2089393A1 Heterocyclic compounds as antiinflammatory agents |
| 08/19/2009 | EP2089383A1 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| 08/19/2009 | EP2089382A1 Substituted diazepan compounds as orexin receptor antagonists |
| 08/19/2009 | EP2089381A1 Indoles which act as via receptor antagonists |
| 08/19/2009 | EP2089376A1 (r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their use |
| 08/19/2009 | EP2089375A2 A method of purification of (s)-n-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride (duloxetine) |
| 08/19/2009 | EP2089368A1 Diaminocyclohexane and diaminocyclopentane derivatives |
| 08/19/2009 | EP2089110A2 Acetylene derivatives and their use for binding and imaging amyloid plaques |
| 08/19/2009 | EP2089061A1 Inhibition of sox9 function fn the treatment of proteogl ycan-associated pathophysiological conditions |
| 08/19/2009 | EP2089049A2 Systemic administration of colony stimulating factors to treat amyloid associated disorders |
| 08/19/2009 | EP2089047A2 Compositions and methods for cardiac tissue protection and regeneration |
| 08/19/2009 | EP2089033A2 Stroke recovery |
| 08/19/2009 | EP2089032A1 A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect |
| 08/19/2009 | EP2089030A2 Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
| 08/19/2009 | EP2089029A2 Pak modulators |
| 08/19/2009 | EP2089028A2 Method for treating delirium |
| 08/19/2009 | EP2089023A2 Methods of treating neuropathic pain with agonists of ppar-gamma |
| 08/19/2009 | EP2089018A2 Methods of treating cognitive impairment and dementia |
| 08/19/2009 | EP2089017A2 Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |